(Press-News.org) Twenty seven per cent of rheumatoid arthritis patients in the study who were on a class of drugs known as anti-TNF therapies did not take them as prescribed in the first six months. Patients from Manchester Royal Infirmary were among those from 60 hospitals around the UK involved in the study.
Researchers from the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester, who led the study, warned that failure to take the drugs correctly, known as 'non-adherence', reduced their effectiveness and may lead to a worsening of patients' disease.
Their results are published today (August 28 2014) in the journal Rheumatology.
One of the study's authors, Dr Kimme Hyrich, reader in rheumatology at The University of Manchester and honorary consultant at Manchester Royal Infirmary added: "If patients do not take their medication as prescribed it is likely to have a significant effect on whether they respond to therapy and could mean that their condition deteriorates more quickly affecting their quality of life. Non-adherence is also a waste of scarce healthcare resources and something that needs to be addressed."
It is not clear from the study whether patient's non-adherence was deliberate or accidental, but for many patients with this chronic disease, it is expected that they will need to remain on these therapies for many years. Research is ongoing to try and understand more about the reasons why patients with arthritis may not always take their medications as prescribed.
Rheumatoid arthritis affects around 400,000 people in the UK and is caused by the body's immune system turning on itself, leading to inflammation pain and swelling in the joints and other internal organs.
The development by Arthritis Research-funded scientists of biologic drugs such as anti-TNF therapy, which block the tumour necrosis factor (TNF) pathway in the inflammatory process that causes rheumatoid arthritis has revolutionised treatment worldwide in the past 10-15 years, and transformed the lives of millions of patients.
But it is expensive, costing between £8,000 and £12,000 a year per patient.
Professor Alan Silman, medical director of Arthritis Research UK, said: "Anti-TNF drugs have transformed the lives of a substantial number of patients with rheumatoid arthritis and related disorders. This success has been at a considerable cost to the NHS but there was always the assumption that patients prescribed these drugs will have the necessary regular injections. The fact that a considerable proportion of patients are missing doses of these very expensive agents is worrying, as clearly their effectiveness would be reduced."
Researchers collected adherence data for 286 patients attending 60 rheumatology clinics across the UK between 2008 and 2012 who had rheumatoid arthritis for seven years. Of these, 27 per cent reported non-adherence to biologic therapy according to the defined criteria at least once over the first six-month period.
Self-reported non-adherence, defined as whether a dose of anti-TNF therapy is taken on the day agreed with the health professional, was recorded at three and six months.
The study captured data from patients attending 60 different hospitals across the UK and was funded by Arthritis Research UK and the Manchester National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit.
INFORMATION:
Arthritis patients failing to take expensive medication, according to new research
2014-08-28
ELSE PRESS RELEASES FROM THIS DATE:
Research demonstrates potential method to better control lung cancer using radiotherapy
2014-08-28
Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients – potentially offering improved local control and survival.
Standard treatment for locally advanced non-small cell lung cancer is a combination of radiotherapy and chemotherapy. Traditionally this is planned in a one-size-fits-all manner but the radiation dose may not always be enough to stop tumour growth.
The potential to increase the radiation dose to the cancerous tissue varies between patients and depends on the size and location of the tumour in relation ...
Dyslexic readers have disrupted network connections in the brain
2014-08-28
Philadelphia, PA, August 28, 2014 – Dyslexia, the most commonly diagnosed learning disability in the United States, is a neurological reading disability that occurs when the regions of the brain that process written language don't function normally.
The use of non-invasive functional neuroimaging tools has helped characterize how brain activity is disrupted in dyslexia. However, most prior work has focused on only a small number of brain regions, leaving a gap in our understanding of how multiple brain regions communicate with one another through networks, called functional ...
Study shows where on the planet new roads should and should not go
2014-08-28
More than 25 million kilometres of new roads will be built worldwide by 2050. Many of these roads will slice into Earth's last wildernesses, where they bring an influx of destructive loggers, hunters and illegal miners.
Now, an ambitious study has created a 'global roadmap' for prioritising road building across the planet, to try to balance the competing demands of development and environmental protection.
The map has two components: an 'environmental-values' layer that estimates that natural importance of ecosystems and a 'road-benefits' layer that estimates the potential ...
Nanoscale assembly line
2014-08-28
This news release is available in German. Cars, planes and many electronic products are now built with the help of sophisticated assembly lines. Mobile assembly carriers, on to which the objects are fixed, are an important part of these assembly lines. In the case of a car body, the assembly components are attached in various work stages arranged in a precise spatial and chronological sequence, resulting in a complete vehicle at the end of the line.
The creation of such an assembly line at molecular level has been a long-held dream of many nanoscientists. "It would ...
Paleontology: Oldest representative of a weird arthropod group
2014-08-28
Biologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a number of 435-million-year-old fossils to a new genus of predatory arthropods. These animals lived in shallow marine habitats and were far less eye-catching than related forms found in Jurassic strata.
Before they sank to the bottom of their shallow marine habitat and were fossilized some 435 million years ago, these arthropods preyed on other denizens of the Silurian seas – although they were not exactly inconspicuous, possessing a bivalved carapace and multiple abdominal limbs. A group of ...
Better classification to improve treatments for breast cancer
2014-08-28
Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of treatments for the disease.
Cancer arises due to genetic changes which cause normal cells to develop into tumors. As we learn more about breast cancer, we are seeing that it is not one single disease – the mutations in the genes that cause different cancers are not alike, and this is why tumors respond differently to treatment and grow at different ...
New study charts the global invasion of crop pests
2014-08-28
Many of the world's most important crop-producing countries will be fully saturated with pests by the middle of the century if current trends continue, according to a new study led by the University of Exeter.
More than one-in-ten pest types can already be found in around half the countries that grow their host crops. If this spread advances at its current rate, scientists fear that a significant proportion of global crop-producing countries will be overwhelmed by pests within the next 30 years.
Crop pests include fungi, bacteria, viruses, insects, nematodes, viroids ...
The Lancet journals: Three-quarters of depressed cancer patients do not receive treatment for depression but a new approach could transform their care
2014-08-28
Three papers published in The Lancet Psychiatry, The Lancet, and The Lancet Oncology reveal that around three-quarters of cancer patients who have major depression are not currently receiving treatment for depression, and that a new integrated treatment programme is strikingly more effective at reducing depression and improving quality of life than current care.
An analysis of data from more than 21 000 patients attending cancer clinics in Scotland, UK, published in The Lancet Psychiatry, found that major depression is substantially more common in cancer patients than ...
Better health care as important as controlling risk factors for heart health
2014-08-28
Hamilton, ON (August 27, 2014) – Keeping a healthy heart may have as much to do with the quality of health care you have available as it does you avoiding risk factors such as smoking, bad diet and little exercise.
A large international study led by researchers at the Population Health Research Institute at McMaster University and Hamilton Health Sciences has found a that low-income countries which have people with the lowest risk factors for cardiovascular problems have the highest rates of cardiovascular events and death, while the high-income countries of people with ...
Researchers investigating new treatment for multiple sclerosis
2014-08-27
MINNEAPOLIS – A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology® Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. The publication is part of the Neurology® family of journals, published by the American Academy of Neurology.
The phase I studies were the first to test the drug candidate in humans. Studies with animals showed that the drug, which is called anti-LINGO-1, or BIIB033, may be able to ...